Virax Biolabs Group Ltd.

  • Market Cap: N/A
  • Industry: Finance
  • ISIN: KYG9495L1251
USD
0.63
-0.01 (-2.24%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

106.16 k

Shareholding (Sep 2024)

FII

0.51%

Held by 3 FIIs

DII

99.49%

Held by 0 DIIs

Promoter

0.00%

How big is Virax Biolabs Group Ltd.?

22-Jun-2025

As of Jun 18, Virax Biolabs Group Ltd. has a market capitalization of 3.56 million, classifying it as a Micro Cap, with Shareholder's Funds of 5.37 million and Total Assets of 5.48 million as of Mar'24; however, there is no valid financial data available for Net Sales or Net Profit for the latest four quarters.

Market Cap: As of Jun 18, Virax Biolabs Group Ltd. has a market capitalization of 3.56 million, categorizing it as a Micro Cap.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales or Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: As of Mar'24, the company reports Shareholder's Funds of 5.37 million and Total Assets of 5.48 million.

Read More

What does Virax Biolabs Group Ltd. do?

22-Jun-2025

Virax Biolabs Group Ltd. is a micro-cap company in the finance industry with a market cap of USD 3.56 million, currently operating at a loss and offering no dividends. Key metrics include a negative return on equity of -73.37% and a price-to-book ratio of 0.41.

Overview: <BR>Virax Biolabs Group Ltd. operates in the finance industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Market cap: USD 3.56 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -999,999.00 <BR>Return on Equity: -73.37% <BR>Price to Book: 0.41 <BR><BR>Contact Details: <BR>Registrar Address: Not available.

Read More

Is Virax Biolabs Group Ltd. technically bullish or bearish?

25-Jun-2025

As of June 2, 2025, the market trend is mildly bearish due to bearish signals from the weekly MACD and moving averages, despite some mildly bullish indicators on the monthly timeframe.

As of 2 June 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, primarily driven by the weekly MACD indicating bearish momentum, along with the daily moving averages also showing a bearish trend. The Bollinger Bands and KST on the weekly timeframe further support this bearish outlook. While the monthly MACD and OBV show mildly bullish signals, they are not strong enough to counteract the bearish indicators present in the weekly timeframe. Overall, the lack of a clear trend in the Dow Theory adds to the uncertainty.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Finance

stock-summary
Market cap

USD 2 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-999,999.00

stock-summary
Return on Equity

-106.41%

stock-summary
Price to Book

0.43

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
11.43%
0%
11.43%
6 Months
-35.16%
0%
-35.16%
1 Year
-63.18%
0%
-63.18%
2 Years
-66.55%
0%
-66.55%
3 Years
-54.04%
0%
-54.04%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Virax Biolabs Group Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-1.90%
EBIT Growth (5y)
-235.10%
EBIT to Interest (avg)
-3.30
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
2.20%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
10.03%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.49
EV to EBIT
0.45
EV to EBITDA
0.46
EV to Capital Employed
-1.70
EV to Sales
-2.77
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-73.37%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 3 Foreign Institutions (0.51%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Virax Biolabs Group Ltd."
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2023 is 0.00% vs -100.00% in Mar 2022",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2023 is -223.53% vs -142.86% in Mar 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'23",
        "Mar'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.70",
          "val2": "-1.70",
          "chgp": "-235.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.50",
          "val2": "-1.70",
          "chgp": "-223.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-669,636.80%",
          "val2": "0.00%",
          "chgp": "-66,963.68%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Mar'23stock-summary
Mar'23
Mar'22
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-5.70
-1.70
-235.29%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-5.50
-1.70
-223.53%
Operating Profit Margin (Excl OI)
-669,636.80%
0.00%
-66,963.68%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2023 is 0.00% vs -100.00% in Mar 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2023 is -223.53% vs -142.86% in Mar 2022

stock-summaryCompany CV
About Virax Biolabs Group Ltd. stock-summary
stock-summary
Virax Biolabs Group Ltd.
Finance
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available